The anti-CD134 agonist antibodies increased CD4+ T cells in pancreatic cancer mouse models and have a synergistic effect with anti-PD-1 inhibitor to eradicating tumor (34). The gene discussed is TNFRSF4; the disease is familial pancreatic carcinoma.